To do this, clinical trials need to use consistent core outcomes. Therefore, HARMONY researchers are running several Delphi Surveys to compile Core Outcome Sets (COS) for specific blood cancers/Hematologic Malignancies.
The HARMONY Alliance Delphi Survey Hackathon for Chronic Myeloid Leukemia (CML), Hodgkin’s Lymphoma (HL), Myeloproliferative Neoplasms (MPN) and Waldenström Macroglobulinaemia (WM) took place on 4 and 18 March 2022. Patients, clinicians, regulators and drug developers were invited to participate. The Delphi Surveys for CML, HL, MPN and WM are now closed. Consensus meetings will take place in May 2022.
The ALL, AML, CLL, NHL, MDS and MM Delphi Surveys are completed.
What are COS and why do we need help from patients, clinicians, regulators and drug developers?
HARMONY
Healthcare Alliance for Resourceful Medicine Offensive against Neoplasms in Hematology
HARMONY and HARMONY PLUS are funded through the Innovative Medicines Initiative (IMI), Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. Funding is received from the IMI 2 Joint Undertaking and is listed under grant agreement for HARMONY No. 116026 and grant agreement for HARMONY PLUS No. 945406. This Joint Undertaking receives support from the European Union’s Horizon 2020 Research and Innovation Programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).
Login
